Abstract
Get full access to this article
View all access options for this article.
References
1.
Incorvaia
D
. Scribe slims down workforce as it readies cardiometabolic genetic meds for clinic. FierceBiotech , January 8, 2025 . Available from: https://www.fiercebiotech.com/biotech/scribe-slims-down-workforce-it-readies-cardiometabolic-genetic-medicines-clinic [Last accessed:
January 11 , 2025
].
2.Intellia Therapeutics . Intellia Therapeutics Announces Anticipated 2025 Milestones and Strategic Reorganization to Prioritize the Advancement of its Late-Stage Programs, NTLA-2002 and Nexiguran Ziclumeran (nex-z) . January 9, 2025 . Available from: https://ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-announces-anticipated-2025-milestones-and [Last accessed:
January 11 , 2025
].
3.Sangamo Therapeutics . Sangamo Therapeutics to Regain Full Rights to Hemophilia A Gene Therapy Program Following Pfizer’s Decision to Cease Development of Giroctocogene Fitelparvovec . December 30, 2024 . Available from: https://investor.sangamo.com/news-releases/news-release-details/sangamo-therapeutics-regain-full-rights-hemophilia-gene-therapy [Last accessed:
January 12 , 2025
].
4.Dyno Therapeutics . Dyno Therapeutics Announces Exercise of Option by Roche for Next-Generation AAV Vector for Neurological Gene Therapy . January 13, 2025 . Available from: https://www.dynotx.com/dyno-therapeutics-announces-exercise-of-option-by-roche-for-next-generation-aav-vector-for-neurological-gene-therapy/ [Last accessed:
January 14 , 2025
].
5.
Gaffney
M
. LinkedIn post , January 2. Available from: https://www.linkedin.com/posts/mark-gaffney-b97a7812b_i-am-happy-to-report-that-oxular-has-been-activity-7280624147506892801-iOOB/ [Last accessed:
January 4 , 2025
].
6.Novartis . Novartis intrathecal onasemnogene abeparvovec Phase III study meets primary endpoint in children and young adults with SMA . December 30, 2024 . Available from: https://www.novartis.com/news/media-releases/novartis-intrathecal-onasemnogene-abeparvovec-phase-iii-study-meets-primary-endpoint-children-and-young-adults-sma [Last accessed:
January 12 , 2025
].
7.Precigen . Precigen completes submission of BLA with request for priority review to the FDA for PRGN-2012 for the treatment of adults with recurrent respiratory papillomatosis . December 30, 2024 . Available from: https://investors.precigen.com/news-releases/news-release-details/precigen-completes-submission-bla-request-priority-review-fda [Last accessed:
January 12 , 2025
].
8.GEMMA Biotherapeutics . GEMMABio Secures $34 Million in Seed Funding to Drive Gene Therapy Advancements . December 23, 2024 . Available from: https://www.prnewswire.com/news-releases/gemmabio-secures-34-million-in-seed-funding-to-drive-gene-therapy-advancements-302338394.html [Last accessed:
January 4 , 2025
].